Galapagos increases share capital through warrant exercises
(Thomson Reuters ONE) -
Mechelen, Belgium; 8 April 2013 - Galapagos NV (Euronext: GLPG) announced today
a capital increase arising from employee warrant exercises.
Since its inception in 1999, Galapagos has used warrant plans to incentivize
personnel and management and have them share in the success of the company.
Following warrant exercises during the exercise period from 9 March 2013 through
29 March 2013, Galapagos issued 197,581 new ordinary shares on 5 April 2013 for
a total capital increase (including issuance premium) of ?1,181,926.39.
CEO Onno van de Stolpe exercised 50,000 warrants, granted in 2008 and which were
due to expire on 25 June 2013. Of these, 20,000 were exercised through a
cashless exercise facility to finance the cash exercise of 30,000 warrants.
Onno van de Stolpe's shareholding in Galapagos thereby increased by 30,000
shares to a total of 355,448 shares, or 1.32% of the outstanding Galapagos
shares.
To date, Galapagos' total share capital amounts to ?145,884,501.48; the total
number of securities conferring voting rights is 26,968,328, which is also the
total number of voting rights (the "denominator"), and all securities conferring
voting rights and all voting rights are of the same category. The total number
of rights (warrants) to subscribe to not yet issued securities conferring voting
rights is 3,123,368, which equals the total number of voting rights that may
result from the exercise of these warrants. Galapagos does not have any
convertible bonds or shares without voting rights outstanding.
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action,
with a large pipeline of four clinical, six pre-clinical, and 30 discovery
small-molecule and antibody programs in cystic fibrosis, inflammation,
antibiotics, metabolic disease, and other indications.
GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment
of rheumatoid arthritis and potentially other inflammatory diseases, about to
enter Phase 2b studies. AbbVie and Galapagos signed a worldwide license
agreement whereby AbbVie will be responsible for further development and
commercialization after Phase 2b. Galapagos has another selective JAK1
inhibitor in Phase 2 in lupus and psoriasis, GSK2586184 (formerly GLPG0778, in-
licensed by GlaxoSmithKline in 2012). GLPG0187 is a novel integrin receptor
antagonist currently in a Phase 1b patient study in metastasis. GLPG0974 is the
first inhibitor of FFA2 to be evaluated clinically for the treatment of IBD;
this program will start a Proof of Concept Phase 2 study in Q2 2013.
The Galapagos Group, including fee-for-service companies BioFocus, Argenta and
Fidelta, has around 800 employees and operates facilities in five countries,
with global headquarters in Mechelen, Belgium. Further information at:
www.glpg.com
CONTACT
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
ir(at)glpg.com
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such forward-
looking statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements speak only as
of the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.
Galapagos increases share capital through warrant exercises:
http://hugin.info/133350/R/1691280/555372.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE
[HUG#1691280]
Unternehmensinformation / Kurzprofil:
Datum: 08.04.2013 - 18:01 Uhr
Sprache: Deutsch
News-ID 246888
Anzahl Zeichen: 5390
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 148 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos increases share capital through warrant exercises"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
